Salarius Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

David Arthur

Algemeen directeur

US$355.7k

Totale compensatie

Percentage CEO-salaris	92.8%
Dienstverband CEO	5.2yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	5.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is David Arthur's beloning veranderd ten opzichte van Salarius Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$6m
Mar 31 2024	n/a	n/a	-US$9m
Dec 31 2023	US$356k	US$330k	-US$13m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$30m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$941k	US$500k	-US$32m
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$677k	US$379k	-US$13m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$9m
Mar 31 2021	n/a	n/a	-US$8m
Dec 31 2020	US$1m	US$340k	-US$8m
Sep 30 2020	n/a	n/a	-US$7m
Jun 30 2020	n/a	n/a	-US$8m
Mar 31 2020	n/a	n/a	-US$7m
Dec 31 2019	US$518k	US$315k	-US$7m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$4m
Mar 31 2019	n/a	n/a	-US$3m
Dec 31 2018	US$275k	US$258k	-US$2m

Compensatie versus markt: De totale vergoeding ($USD 355.70K ) David } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 471.55K ).

Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

David Arthur (61 yo)

5.2yrs

Tenure

US$355,700

Compensatie

Mr. David J. Arthur, M.B.A., has been President at Salarius Pharmaceuticals, Inc since July 19, 2019 and Chief Executive Officer & Director at Salarius Pharmaceuticals, Inc. since July 2019. Mr. Arthur ser...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Arthur	CEO, President & Director	5.2yrs	US$355.70k	0.43% € 8.4k
Jonathan Lieber	Independent Director	4.3yrs	US$53.76k	0.026% € 503.4
Bruce McCreedy	Independent Director	5.2yrs	US$45.26k	0.012% € 246.2
Arnold Hanish	Independent Director	5.2yrs	US$67.26k	0.029% € 563.6
William McVicar	Chairman of the Board	5.2yrs	US$82.26k	0.025% € 486.9
Tess Burleson	Independent Director	5.2yrs	US$64.76k	0.024% € 465.0

5.2yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FP10 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).

Salarius Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Insufficient new directors

Salarius Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Recent updates

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Insufficient new directors

Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals, Inc. announced that it has received $6.000001 million in funding

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. to Present SP-3164 Targeted Protein Degrader Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. Announces Investigators Present Clinical Data on Its Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Reports Impairment of Goodwill for the Three Months Ended September 30, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on Sp-3164 At the 5Th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals, Inc. Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for Ongoing Trial of Seclidemstat as A Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Salarius Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX) acquired certain assets of DeuteRx, including DRX-164 for approximately $220 million.

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Second quarter 2021 earnings released: US$0.069 loss per share (vs US$0.13 loss in 2Q 2020)

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’S Safety, Dosing, and Drug Activity At American Society of Clinical Oncology (Asco) 2021 Annual Meeting

Salarius Pharmaceuticals, Inc. Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.22 loss in 1Q 2020)

Full year 2020 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2019)

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Salarius Pharmaceuticals, Inc. Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Salarius Pharmaceuticals, Inc. Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

New 90-day high: €1.16

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Salarius Pharmaceuticals, Inc. Announces Developing Seclidemstat

New 90-day high: €1.05

New 90-day high: €0.88

Third quarter 2020 earnings released: US$0.096 loss per share

Revenue beats expectations

New 90-day low: €0.66

New 90-day low: €0.67

New 90-day low - €0.79

New 90-day low - €0.83

Earnings released

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.353451 million.